Oliceridine used for patient-controlled analgesia on postoperative quality of recovery in patients undergoing laparoscopic gynecological tumour resection: a randomized clinical trial.

TL;DR

Oliceridine-based patient-controlled analgesia improved postoperative quality of recovery (QoR-40) on postoperative day 1 and within 3 days compared to sufentanil in patients undergoing laparoscopic gynecological tumour resection. Analgesic efficacy was comparable between drugs, with oliceridine showing lower postoperative frailty scores and reduced nausea/vomiting.

Key findings

• Oliceridine PCIA produced significantly higher QoR-40 scores on postoperative day 1 (182.9 vs 177.5) and sustained superiority over 3 postoperative days
• Pain control (NRS scores) and anxiety (HADS-A) were equivalent between oliceridine and sufentanil groups
• Oliceridine associated with lower FRAIL scores on postoperative day 2, indicating reduced frailty, and lower incidence of postoperative nausea and vomiting
• Randomized controlled trial of 94 female patients undergoing elective laparoscopic gynecological tumor resection

Why this matters at the bedside

Suggests oliceridine, a biased μ-opioid agonist, may offer recovery advantages beyond pain control in gynecological surgery, potentially due to reduced adverse effects and opioid-related complications; findings support consideration of oliceridine for perioperative analgesia in this surgical population.